Zika virus is not thermostable: very effective virus inactivation during heat treatment (pasteurization) of human serum albumin

Transfusion

Volumn 57, Issue 3, 2017, Pages 797-801

  Farcet, Maria R ^a   Kreil, Thomas R ^a  

^a Global Pathogen Safety   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN SERUM ALBUMIN; SERUM ALBUMIN;

ARTICLE; BOVINE VIRAL DIARRHEA VIRUS 1; COMPARATIVE STUDY; CONTROLLED STUDY; DENGUE VIRUS; HEAT SENSITIVITY; HUMAN; LIMIT OF DETECTION; NONHUMAN; PASTEURIZATION; THERMOSTABILITY; TICK BORNE ENCEPHALITIS VIRUS; VIRUS INACTIVATION; VIRUS STRAIN; WEST NILE VIRUS; ZIKA VIRUS; ANIMAL; BOVINE; CHEMISTRY; DISINFECTION; HEAT; PROCEDURES;

ANIMALS; CATTLE; DISINFECTION; HOT TEMPERATURE; HUMANS; SERUM ALBUMIN; VIRUS INACTIVATION; ZIKA VIRUS;

EID: 85007019235     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13953     Document Type: Article

References (25)

1. Lazear HM, Diamond MS. Zika virus: new clinical syndromes and its emergence in the Western Hemisphere. J Virol 2016;90:4864–75.
2. Duffy MR, Chen TH, Hancock WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 2009;360:2536–43.
3. Musso D, Nhan T, Robin E, et al. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. Euro Surveill 2014;19:20761.
4. Pealer LN, Marfin AA, Petersen LR, et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003;349:1236–45.
5. Tambyah PA, Koay ES, Poon ML, et al. Dengue hemorrhagic fever transmitted by blood transfusion. N Engl J Med 2008;359:1526–7.
6. European Centre for Disease Prevention and Control. Rapid risk assessment. Zika virus disease epidemic: potential association with microcephaly and Guillain-Barré syndrome. Fourth update, 9 March 2016 [Internet]. Stockholm: ECDC; 2016 [cited 2016 Sep 05]. Available from: http://ecdc.europa.eu/en/publications/Publications/zika-virus-rapid-risk-assessment-9-march-2016.pdf.
7. US Food and Drug Administration. Recommendations for donor screening, deferral, and product management to reduce the risk of transfusion-transmission of Zika virus; guidance for industry. Silver Spring (MD): US Food and Drug Administration; February 2016 [cited 2016 Sep 05]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM486360.pdf.
8. Kreil TR, Berting A, Kistner O, et al. West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003;43:1023–8.
9. Remington KM, Trejo SR, Buczynski G, et al. Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products. Vox Sang 2004;87:10–8.
10. Xie YW, Chan PK, Szeto CK, et al. Clearance of Dengue virus in the plasma-derived therapeutic proteins. Transfusion 2008;48:1342–7.
11. Leydold SM, Farcet MR, Kindermann J, et al. Chikungunya virus and the safety of plasma products. Transfusion 2012;52:2122–30.
12. Sirohi D, Chen Z, Sun L, et al. The 3.8 Å resolution cryo-EM structure of Zika virus. Science 2016;352:467–70.
13. Kostyuchenko VA, Lim EXY, Zhang S, et al. Structure of the thermally stable Zika virus. Nature 2016;533:425-8.
14. AABB SmartBrief. Zika virus structure remains stable in elevated heat. April 27, 2016. [cited 2016 Nov 28]. Available from: http://www.aabb.org/programs/publications/Pages/smartbrief.aspx.
15. Lanciotti RS, Lambert AJ, Holodniy M, et al. Phylogeny of Zika virus in Western Hemisphere, 2015. Emerg Infect Dis 2016;22:933–5.
16. Heang V, Yasuda CY, Sovann L, et al. Zika virus infection, Cambodia, 2010. Emerg Infect Dis 2012;18:349–50.
17. Haddow AD, Schuh AJ, Yasuda CY, et al. Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage. PLoS Negl Trop Dis 2012;6:e1477.
18. Kundi M. One-hit models for virus inactivation studies. Antiviral Res 1999;41:145–52.
19. Kreil TR, Unger U, Orth SM, et al. H5N1 influenza virus and the safety of plasma products. Transfusion 2007;47:452–9.
20. Farcet MR, Kindermann J, Modrof J, et al. Inactivation of hepatitis A variants during heat treatment (pasteurization) of human serum albumin. Transfusion 2012;52:181–7.
21. European Medicines Agency, Committee for Proprietary Medicinal Products (CPMP). CPMP note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses (CPMP/BWP/268/95/rev). London: European Medicines Agency; 1996.
22. Outbreak News Today. Transfusion-associated Zika virus reported in Brazil [Internet]. 2015 [cited 2016 Sep 05] Available from: http://outbreaknewstoday.com/transfusion-associated-zika-virus-reported-in-brazil-76935/.
23. Reuters. Brazil reports Zika infection from blood transfusions [Internet]. 2016 [cited 2016 Sep 05]. Available from: http://www.reuters.com/article/us-health-zika-brazil-blood-idUSKCN0VD22N.
24. Barjas-Castro ML, Angerami RN, Cunha MS, et al. Probable transfusion-transmitted Zika virus in Brazil. Transfusion 2016;56:1684-8.
25. US Food and Drug Administration. News Release. FDA allows use of investigational test to screen blood donations for Zika virus. March 30, 2016 [cited 2016 Sep 05]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm493081.htm.